Merck’s Keytruda Now FDA-Approved for Advanced Non-Small Cell Lung Cancer
News
Merck & Co. recently announced the US Food and Drug Administration has granted Keytruda (pembrolizumab) accelerated approval as a treatment for patients with advanced (metastatic) non-small cell lung cancer (NSCLC) who have not ... Read more